Hemolytically active (acylated) alpha-hemolysin elicits interleukin-1β (IL-1β) but augments the lethality of Escherichia coli by an IL-1- and tumor necrosis factor-independent mechanism

Infection and Immunity

Volumn 66, Issue 9, 1998, Pages 4215-4221

  Gleason, Thomas G ^a   Webster Houlgrave, C ^a   May, Addison K ^b   Crabtree, Traves D ^a   Sawyer, Robert G ^a   Denham, Woody ^c   Norman, James G ^c   Pruett, Timothy L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Kentucky   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOLYSIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR;

ACYLATION; ARTICLE; BACTERIAL VIRULENCE; CYTOKINE RELEASE; EFFECTOR CELL; ESCHERICHIA COLI; GENE EXPRESSION; MONOCYTE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 3543001599     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.9.4215-4221.1998     Document Type: Article

References (64)

1. Acton, R. D., P. S. Dahlberg, M. E. Uknis, G. Klaerner, G. S. Fink, J. G. Norman, and D. L. Dunn. 1996. Differential sensitivity to Escherichia coli infection in mice lacking tumor necrosis factor p55 or interleukin-1 p80 receptors. Arch. Surg. 131:1216-1221.
2. Apicella, M. A., J. M. Griffiss, and H. Schneider. 1994. Isolation and characterization of lipopolysaccharides, lipooligosaccharides, and lipid A. Methods Enzymol. 235:242-252.
3. Bhakdi, S., S. Greulich, M. Muhly, B. Eberspacher, H. Becker, A. Thiele, and F. Hugo. 1989. Potent leukocidal action of Escherichia coli hemolysin mediated by permeabilization of target cell membranes. J. Exp. Med. 169:737-754.
4. Bhakdi, S., and E. Martin. 1991. Superoxide generation by human neutrophils induced by low doses of Escherichia coli hemolysin. Infect. Immun. 59: 2955-2962.
5. Bhakdi, S., M. Muhly, S. Korom, and G. Schmidt. 1990. Effects of Escherichia coli hemolysin on human monocytes, cytocidal action and stimulation of interleukin-1 release. J. Clin. Invest. 85:1746-1753.
6. Blanco, M., J. E. Blanco, M. P. Alonso, and J. Blanco. 1994. Virulence factors and O groups of Escherichia coli strains isolated from cultures of blood specimens from urosepsis and non-urosepsis patients. Microbiologia 10:249-256.
7. Blight, M. A., and I. B. Holland. 1990. Structure and function of haemolysin B, P-glycoprotein and other members of a novel family of membrane translocators. Mol. Microbiol. 4:873-880.
8. Boehm, D. F., R. A. Welch, and I. S. Snyder. 1990. Domains of Escherichia coli hemolysin (HlyA) involved in binding of calcium and erythrocyte membranes. Infect. Immun. 58:1959-1964.
9. Bohach, G. A., and I. S. Snyder. 1985. Chemical and immunological analysis of the complex structure of Escherichia coli alpha-hemolysin. J. Bacteriol. 164:1071-1080.
10. Bohach, G. A., and I. S. Snyder. 1986. Composition of affinity-purified alpha-hemolysin of Escherichia coli. Infect. Immun. 53:435-437.
11. Brauner, A., M. Katouli, and C. G. Ostenson. 1995. P-fimbriation and haemolysin production are the most important virulence factors in diabetic patients with Escherichia coli bacteraemia: a multivariate statistical analysis of seven bacterial virulence factors. J. Infect. 31:27-31.
12. Burnette, W. N. 1981. Western blotting: electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal. Biochem. 112:195-203.
13. Calvin, N. M., and P. C. Hanawall. 1988. High-efficiency transformation of bacterial cells by electroporation. J. Bacteriol. 170:2796-2801.
14. Cavalieri, S. J., G. A. Bohach, and I. S. Snyder. 1984. Escherichia coli alpha-hemolysin: characteristics and probable role of pathogenicity. Microbiol. Rev. 48:326-343.
15. Cavalieri, S. J., and I. S. Snyder. 1982. Cytotoxic activity of partially purified Escherichia coli alpha haemolysin. J. Med. Microbiol. 15:11-21.
16. Cavalieri, S. J., and I. S. Snyder. 1982. Effect of Escherichia coli alpha-hemolysin on human peripheral leukocyte function in vitro. Infect. Immun. 37:966-974.
17. Centers for Disease Control and Prevention. 1996. National Nosocomial Infections Surveillance (NNIS) report, data summary from Oct. 1986-Apr. 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System. Am. J. Infect. Control 24:380-388.
18. Cluff, C. W., M. Garcia, and H. K. Ziegler. 1990. Intracellular hemolysin-producing Listeria monocytogenes strains inhibit macrophage-mediated antigen processing. Infect. Immun. 58:3601-3612.
19. Colotta, F., S. Saccani, J. G. Giri, S. K. Dower, J. E. Sims, M. Introna, and A. Mantovani. 1996. Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes. J. Immunol. 156:2534-2541.
20. Czuprynski, C. J., and R. A. Welch. 1995. Biologic effects of RTX toxins: the possible role of lipopolysaccharide. Trends Microbiol. 3:480-483.
21. Dower, W. W. J., J. F. Miller, and C. W. Ragsdale. 1988. High efficiency transformation of E. coli by high voltage electroporation. Nucleic Acids Res. 16:6127-6145.
22. Fantuzzi, G., H. Zheng, R. Faggioni, F. Benign, P. Ghezzi, J. D. Sipe, A. R. Shaw, and C. A. Dinarello. 1996. Effect of endotoxin in IL-1β-deficient mice. J. Immunol. 157:291-296.
23. Felmlee, T., S. Pellet, and R. A. Welch. 1985. Nucleotide sequence of an Escherichia coli chromosomal hemolysin. J. Bacteriol. 163:94-105.
24. Giri, J. G., J. Wells, S. K. Dower, C. E. McCall, R. N. Guzman, J. Slack, T. A. Bird, K. Shanebeck, K. H. Grabstein, J. E. Sims, and M. R. Alderson. 1994. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J. Immunol. 153:5802-5809.
25. Gleason, T. G., R. G. Sawyer, C. W. Houlgrave, and T. L. Pruett. 1997. Killed bacterial preparations protect against live bacterial infection better than endotoxin: tolerance is not unique to endotoxin, p. 67-70. In Owen H. Wangensteen Surgical Forum of the 83rd Annual Clinical Congress 1997. American College of Surgeons, Chicago, III.
26. The HA-1A Sepsis Study Group. 1991. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind placebo-controlled trial. N. Engl. J. Med. 324:429-436.
27. Ikaheimo, R., A. Siitonen, U. Karkkainen, and P. H. Makela. 1993. Virulence characteristics of Escherichia coli in nosocomial urinary tract infection. Clin. Infect. Dis. 16:785-791.
28. Issartel, J.-P., V. Koronakis, and C. Hughes. 1991. Activation of Escherichia coli prohaemolysin to the mature toxin by acyl carrier protein-dependent fatty acylation. Nature 351:759-761.
29. Korhonen, T. K., M. V. Valtonen, J. Parkkinen, V. Vaisanen-Rhen, J. Finne, F. Orskov, I. Orskov, S. B. Svenson, and P. H. Makela. 1985. Serotypes, hemolysin production, and receptor recognition of Escherichia coli strains associated with neonatal sepsis and meningitis. Infect. Immun. 48:486-491.
30. Li, P., H. Allen, S. Banerjee, S. Franklin, L. Herzog, C. Johnston, J. McDowell, M. Paskind, L. Rodman, J. Salfeld, E. Twone, D. Tracey, S. Warwell, F.-Y. Wei, W. Wong, R. Kamen, and T. Seshadri. 1995. Mice deficient in IL-1b-converting enzyme are defective in production of mature IL-1b and resistant to endotoxic shock. Cell 80:401-411.
31. Lobo, A. L., and R. A. Welch. 1994. Identification and assay of RTX family of cytolysins. Methods Enzymol. 235:667-678.
32. Ludwig, A., F. Garcia, S. Bauer, T. Jarchau, R. Benz, J. Hoppe, and W. Goebel. 1996. Analysis of the in vivo activation of hemolysin (HlyA) from Escherichia coli. J. Bacteriol. 178:5422-5430.
33. Mackman, N., J.-M. Nicaud, L. Gray, and I. B. Holland. 1985. Genetical and functional organization of the Escherichia coli haemolysin determinant 2001. Mol. Gen. Genet. 201:282-288.
34. Malek, A. M., S. Izumo, and S. L. Alper. 1997. Quantitative densitometric analysis using a commercially available handheld CCD digital camera. BioTechniques 22:1150-1153.
35. May, A, K., R. G. Sawyer, T. Gleason, A. Whitworth, and T. L. Pruett. 1996. In vivo cytokine response to Escherichia coli alpha-hemolysin determined with genetically engineered hemolytic and nonhemolytic E. coli variants. Infect. Immun. 64:2167-2171.
36. Molloy, R. G., M. O'Riordain, R. Holzheimer, M. Nestor, K. Collins, J. A. Mannick, and M. L. Rodrick. 1993. Mechanisms of increased tumor necrosis factor after thermal injury. J. Immunol. 151:2142-2149.
37. Nicaud, J.-M., N. Mackman, L. Gray, and I. B. Holland. 1985. Characterization of HlyC and mechanism of activation and secretion of hemolysin from E. coli 2001. FEBS Lett. 187:339-344.
38. Norman, J. G., G. Fink, M. Franz, J. Guffey, G. Carter, B. Davison, C. Sexton, and M. Glaccum. 1996. Active interleukin-1 receptor required for maximal progression of acute pancreatitis. Ann. Surg. 223:163-169.
39. Norman, J. G., G. W. Fink, C. Sexton, and G. Carter. 1996. Transgenic animals demonstrate a role for the IL-1 receptor in regulating IL-1beta gene expression at steady-state and during systemic stress induced by acute pancreatitis. J. Surg. Res. 63:231-236.
40. Oldenburg, H. S. A., J. H. Pruitt, D. D. Lazarus, M. A. Rogy, R. Chizzonite, S. F. Lowry, and L. L. Moldauer. 1995. Interleukin 1 binding to its type I, but not type II receptor, modulates the in vivo acute phase response. Cytokine 7: 510-516.
41. Oropeza-Wekerle, R. L., W. Speth, B. Imhof, I. Gentschev, and W. Goebel. 1990. Translocation and compartmentalization of Escherichia coli hemolysin (HlyA). J. Bacteriol. 172:3711-3717.
42. Pellett, S., D. F. Boehm, I. S. Snyder, G. Rowe, and R. A. Welch. 1990. Characterization of monoclonal antibodies against the Escherichia coli hemolysin. Infect. Immun. 58:822-827.
43. Pfeffer, K., T. Matsuyama, T. M. Kundig, A. Wakeman, K. Kishihara, A. Shahinian, K. Wiegmann, P. S. Ohashi, M. Knonke, and T. W. Mak. 1993. Mice deficient for the 55kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457-467.
44. Phase III rhIL-1ra Sepsis Syndrome Study Group. 1994. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 271:1836-1843. (Erratum, 272:1170, 1994.)
45. Pruitt, J. H., M. B. Welborn, P. D. Edwards, T. R. Harward, J. W. Seeger, T. D. Martin, C. Smith, J. A. Kenney, R. I. Wesdorp, S. Meijer, M. A. Cuesta, A. Abouhanze, E. M. Copeland III, J. Giri, J. E. Sims, L. L. Moldawer, and H. S. Oldenburg. 1996. Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome. Blood 87:3282-3288.
46. Rogers, H. W., K. C. F. Sheehan, L. M. Brunt, S. K. Dower, E. R. Unanue, and R. D. Schreiber. 1992. Interleukin 1 participates in the development of anti-Listeria responses in normal and SCID mice. Proc. Natl. Acad. Sci. USA 89:1011-1015.
47. Sandhu, G. S., B. W. Eckloff, and B. C. Kline. 1991. Chemiluminescent substrates increase sensitivity of antigen detection in Western blots. BioTechniques 11:14-16.
48. Saravolatz, L. D., J. C. Wherry, C. Spooner, N. Markowitz, R. Allfred, K. Remick, M. Fournel, and J. E. Pennington. 1994. Clinical safety, tolerability and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor alpha. J. Infect. Dis. 169:214-217.
49. Saxen, H., E. Tarkka, P. Hannikainen, R. Nikku, M. Rautio, and A. Siitonen. 1996. Escherichia coli and appendicitis: phenotypic characteristics of E. coli isolates from inflamed and noninflamed appendices. Clin. Infect. Dis. 23: 1038-1042.
50. Siegried, L., H. Puzova, M. Kmetova, and A. Kerestesova. 1992. Killing of alpha-haemolytic and non-haemolytic Escherichia coli strains in human serum and polymorphonuclear leucocytes. J. Med. Microbiol. 37:3-7.
51. Siitonen, A., A. Takala, Y. A. Ratiner, A. Pere, and P. H. Makela. 1993. Invasive Escherichia coli infections in children: bacterial characteristics in different age groups and clinical entities. Pediatr. Infect. Dis. 12:606-612.
52. Sims, J. E., M. A. Gayle, J. L. Slack, M. R. Alderson, T. A. Bird, J. G. Gin, F. Colotta, F. Re, A. Mantovani, K. Shanebeck, K. H. Grabstein, and S. K. Dower. 1993. Interleukin 1 signaling occurs via the type I receptor. Proc. Natl. Acad. Sci. USA 90:6155-6159.
53. Snyder, I. S., and N. A. Koch. 1966. Production and characteristics of hemolysins of Escherichia coli. J. Bacteriol. 91:763-767.
54. Stanley, P., L. Packman, V. Koronakis, and C. Hughes. 1994. Fatty acylation of two internal lysine residues required for the toxic activity of Escherichia coli hemolysin. Science 266:1992-1996.
55. Stanley, P. L., P. Diaz, M. J. Bailey, D. Gygi, A. Juarez, and C. Hughes. 1993. Loss of activity in the secreted form of Escherichia coli haemolysin caused by an rfaP lesion in core lipopolysaccharide assembly. Mol. Microbiol. 10:781-787.
56. Strong, D. M., A. A. Ahmed, G. B. Thurman, and K. W. Sell. 1973. In vitro stimulation of murine spleen cells using a microculture system and a multiple automated sample harvester. J. Immunol. Methods 2:279-287.
57. Theodos, C. M., A. Shankar, A. L. Glasebrook, W. D. Roeder, and R. G. Titus. 1994. The effect of treating with anti-interleukin-1 receptor antibody on the course of experimental murine cutaneous leishmaniasis. Parasite Immunol. 16:571-577.
58. The TNF-α Mab Sepsis Study Group. 1995. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 273:934-941.
59. Welch, R. A., E. P. Dellinger, B. Minshew, and S. Falkow. 1981. Haemorysin contributes to virulence of extra-intestinal E. coli infections. Nature 294:665-667.
60. Welch, R. A., and S. Falkow. 1984. Characterization of Escherichia coli hemolysins conferring quantitative differences in virulence. Infect. Immun. 43:156-160.
61. Welch, R. A., R. Hull, and S. Falkow. 1983. Molecular cloning and physical characterization of a chromosomal hemolysin from Escherichia coli. Infect. Immun. 42:178-186.
62. Welkos, S., and A. O'Brien. 1994. Determination of median lethal and infectious doses in animal model systems. Methods Enzymol. 235:29-39.
63. The XOMA Sepsis Study Group. 1991. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gramnegative sepsis. JAMA 266:1097-1102.
64. Zheng, H., D. Fletcher, W. Kozak, M. Jiang, K. Hofmann, C. A. Conn, D. Soszynski, C. Grabiec, M. E. Trumbauer, A. Shaw, M. J. Kostura, K. Stevens, H. Rosen, R. J. North, H. Y. Chen, M. J. Tocci, M. J. Kluger, and L. H. T. Van der Ploeg. 1995. Resistance to fever induction and impaired acute-phase response in interleukin-1β deficient mice. Immunity 3:9-19.